Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Wilmott JS, Menzies AM, Leduc C, Stagg J, Routy B, Long GV, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL, Smyth MJ. Lepletier A, et al. Among authors: merelli b. Clin Cancer Res. 2020 Jul 15;26(14):3671-3681. doi: 10.1158/1078-0432.CCR-19-3925. Epub 2020 Apr 28. Clin Cancer Res. 2020. PMID: 32345648
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P. Chiarion Sileni V, et al. Among authors: merelli b. J Exp Clin Cancer Res. 2014 Apr 4;33(1):30. doi: 10.1186/1756-9966-33-30. J Exp Clin Cancer Res. 2014. PMID: 24708900 Free PMC article. Clinical Trial.
Nras in melanoma: targeting the undruggable target.
Mandalà M, Merelli B, Massi D. Mandalà M, et al. Among authors: merelli b. Crit Rev Oncol Hematol. 2014 Nov;92(2):107-22. doi: 10.1016/j.critrevonc.2014.05.005. Epub 2014 Jun 12. Crit Rev Oncol Hematol. 2014. PMID: 24985059 Review.
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, Mandalà M. Massi D, et al. Among authors: merelli b. Ann Oncol. 2014 Dec;25(12):2433-2442. doi: 10.1093/annonc/mdu452. Epub 2014 Sep 15. Ann Oncol. 2014. PMID: 25223485 Free article.
KIT genetic alterations in anorectal melanomas.
Santi R, Simi L, Fucci R, Paglierani M, Pepi M, Pinzani P, Merelli B, Santucci M, Botti G, Urso C, Massi D. Santi R, et al. Among authors: merelli b. J Clin Pathol. 2015 Feb;68(2):130-4. doi: 10.1136/jclinpath-2014-202572. Epub 2014 Nov 14. J Clin Pathol. 2015. PMID: 25398993
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M. Massi D, et al. Among authors: merelli b. Ann Oncol. 2015 Sep;26(9):1980-1987. doi: 10.1093/annonc/mdv255. Epub 2015 Jun 2. Ann Oncol. 2015. PMID: 26037795 Free article.
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.
Falanga A, Marchetti M, Massi D, Merelli B, Verzeroli C, Russo L, Rulli E, Tondini C, Legramandi L, Nassini R, Scatena C, De Logu F, Cattaneo L, Mandalà M. Falanga A, et al. Among authors: merelli b. J Am Acad Dermatol. 2016 Jun;74(6):1254-1256.e4. doi: 10.1016/j.jaad.2015.11.006. J Am Acad Dermatol. 2016. PMID: 27185428 No abstract available.
61 results